United States · Platforms & data · MarketBeat

Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup

Published by MarketBeat · United States 1 h ago

Citigroup decreased their price objective on shares of Krystal Biotech from $416.00 to $412.00 and set a "buy" rating on the stock in a report on Tuesday.

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

Seeking Alpha

AppLovin Q3 2026 earnings preview: Revenue expected to rise Y/Y

The Motley Fool

Chegg (CHGG) Q3 2026 Earnings Call Transcript

MarketWatch

‘It’s good to be old’: I’ve been invited to a dozen free meals that turn into annuity sales pitches. Should I stop going?

CNBC

Stock market after midterm elections: What S&P 500 history shows

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Morningstar